Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

David Marin, Sarah Marktel, Richard Szydlo, John P. Klein, Marco Bua, Nicola Foot, Eduardo Olavarria, Pat Shepherd, Edward Kanfer, John M. Goldman, Jane F. Apperley

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Until the recent introduction of imatinib, interferon alfa was the standard treatment for patients in the chronic phase of chronic myeloid leukaemia. We compared survival of 143 such patients, who did not respond to interferon alfa and were treated with imatinib, with that of 246 historical controls who received conventional treatment. Patients on imatinib showed an overall survival advantage (relative risk 0.54, 95% CI 0.31-0.93). However, although patients on imatinib who achieved at least some degree of cytogenetic response after 6 months had better survival than controls (0.13, 0.05-0.39), those with no cytogenetic response to imatinib had significantly worse survival (1.69, 1.09-2.64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis.

Original languageEnglish
Pages (from-to)617-619
Number of pages3
JournalLancet
Volume362
Issue number9384
DOIs
Publication statusPublished - Aug 23 2003

Fingerprint

Leukemia, Myeloid, Chronic Phase
Interferon-alpha
Cytogenetics
Survival
Imatinib Mesylate
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. / Marin, David; Marktel, Sarah; Szydlo, Richard; Klein, John P.; Bua, Marco; Foot, Nicola; Olavarria, Eduardo; Shepherd, Pat; Kanfer, Edward; Goldman, John M.; Apperley, Jane F.

In: Lancet, Vol. 362, No. 9384, 23.08.2003, p. 617-619.

Research output: Contribution to journalArticle

Marin, D, Marktel, S, Szydlo, R, Klein, JP, Bua, M, Foot, N, Olavarria, E, Shepherd, P, Kanfer, E, Goldman, JM & Apperley, JF 2003, 'Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa', Lancet, vol. 362, no. 9384, pp. 617-619. https://doi.org/10.1016/S0140-6736(03)14182-7
Marin, David ; Marktel, Sarah ; Szydlo, Richard ; Klein, John P. ; Bua, Marco ; Foot, Nicola ; Olavarria, Eduardo ; Shepherd, Pat ; Kanfer, Edward ; Goldman, John M. ; Apperley, Jane F. / Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. In: Lancet. 2003 ; Vol. 362, No. 9384. pp. 617-619.
@article{823e5f1de4b849f7a9928c670cc21506,
title = "Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa",
abstract = "Until the recent introduction of imatinib, interferon alfa was the standard treatment for patients in the chronic phase of chronic myeloid leukaemia. We compared survival of 143 such patients, who did not respond to interferon alfa and were treated with imatinib, with that of 246 historical controls who received conventional treatment. Patients on imatinib showed an overall survival advantage (relative risk 0.54, 95{\%} CI 0.31-0.93). However, although patients on imatinib who achieved at least some degree of cytogenetic response after 6 months had better survival than controls (0.13, 0.05-0.39), those with no cytogenetic response to imatinib had significantly worse survival (1.69, 1.09-2.64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis.",
author = "David Marin and Sarah Marktel and Richard Szydlo and Klein, {John P.} and Marco Bua and Nicola Foot and Eduardo Olavarria and Pat Shepherd and Edward Kanfer and Goldman, {John M.} and Apperley, {Jane F.}",
year = "2003",
month = "8",
day = "23",
doi = "10.1016/S0140-6736(03)14182-7",
language = "English",
volume = "362",
pages = "617--619",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9384",

}

TY - JOUR

T1 - Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

AU - Marin, David

AU - Marktel, Sarah

AU - Szydlo, Richard

AU - Klein, John P.

AU - Bua, Marco

AU - Foot, Nicola

AU - Olavarria, Eduardo

AU - Shepherd, Pat

AU - Kanfer, Edward

AU - Goldman, John M.

AU - Apperley, Jane F.

PY - 2003/8/23

Y1 - 2003/8/23

N2 - Until the recent introduction of imatinib, interferon alfa was the standard treatment for patients in the chronic phase of chronic myeloid leukaemia. We compared survival of 143 such patients, who did not respond to interferon alfa and were treated with imatinib, with that of 246 historical controls who received conventional treatment. Patients on imatinib showed an overall survival advantage (relative risk 0.54, 95% CI 0.31-0.93). However, although patients on imatinib who achieved at least some degree of cytogenetic response after 6 months had better survival than controls (0.13, 0.05-0.39), those with no cytogenetic response to imatinib had significantly worse survival (1.69, 1.09-2.64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis.

AB - Until the recent introduction of imatinib, interferon alfa was the standard treatment for patients in the chronic phase of chronic myeloid leukaemia. We compared survival of 143 such patients, who did not respond to interferon alfa and were treated with imatinib, with that of 246 historical controls who received conventional treatment. Patients on imatinib showed an overall survival advantage (relative risk 0.54, 95% CI 0.31-0.93). However, although patients on imatinib who achieved at least some degree of cytogenetic response after 6 months had better survival than controls (0.13, 0.05-0.39), those with no cytogenetic response to imatinib had significantly worse survival (1.69, 1.09-2.64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis.

UR - http://www.scopus.com/inward/record.url?scp=0041966018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041966018&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)14182-7

DO - 10.1016/S0140-6736(03)14182-7

M3 - Article

VL - 362

SP - 617

EP - 619

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9384

ER -